ROIV vs SYRE
ROIV: Roivant Sciences is a biopharma-tech incubator that uses a 'Vant' subsidiary model and computational discovery tools to accelerate the development of transformative therapies for autoimmune and inflammatory diseases. SYRE: Spyre is developing a portfolio of long-acting engineered antibodies and combinations targeting validated inflammatory pathways in IBD and rheumatic diseases with potential for quarterly dosing convenience.
Side-by-side fundamentals
| Metric | ROIV | SYRE | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $34.91 | $99.17 | |
| Market cap as of 2026-07-23 | $25.1B | $8.6B | |
| PEG as of 2026-07-23 | -0.68 | n/a | |
| Net margin as of 2026-07-23 | -3629.2% | -22158.5% | ROIV higher |
| Gross margin as of 2026-07-23 | +84.4% | n/a | |
| Operating margin as of 2026-07-23 | -6102.2% | -17559.3% | ROIV higher |
| ROE as of 2026-07-23 | -6.9% | -31.3% | ROIV higher |
| ROA as of 2026-07-23 | -5.7% | -27.8% | ROIV higher |
| Debt / equity as of 2026-07-23 | 0.00 | 0.00 | Tie |
| Revenue growth (YoY) as of 2026-07-23 | -89.2% | n/a | |
| Revenue CAGR (3y) SEC XBRL | -36.0% | n/a | |
| Beta as of 2026-07-23 | 1.12 | 2.97 | |
| 1-year return as of 2026-07-22 close | +203.6% | +501.4% | SYRE higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.